Coronary disease & ACS

Use of coronary artery bypass graft surgery and percutaneous coronary intervention and associated outcomes in the ISCHEMIA trial

Am Heart JPublished Secondary analysis of the ISCHEMIA randomised trial

Primary result · Adjusted primary event rate, comparative cohort (n = 1,203; 385 CABG, 818 PCI)Result — go to the resultDifference 1.3% 95% CI −4.9% to 7.7%

Authors' conclusion

There was no statistical evidence of a difference between PCI and CABG in the intermediate SYNTAX group but the CIs are broad, reflecting uncertainty.

Study context

Population
Patients with stable coronary disease in the invasive arm of ISCHEMIA who underwent CABG or PCI within 180 days of randomisationdescriptive cohort
Participants
1,935 patients
Comparison
CABG vs PCI
  • CABGn = 485
  • PCIn = 1,450reference
Primary endpoint
CV death, MI, or hospitalization for unstable angina, HF, or resuscitated cardiac arrest
Follow-up
4 years
Methodological detailsobservational comparison of CABG vs PCI, adjusted analysis
  • Observational comparison of CABG vs PCI
  • Adjusted analysis

Primary result

As reported in the abstract

Adjusted primary event rate, comparative cohort (n = 1,203; 385 CABG, 818 PCI)

Difference

1.3%

95% CI −4.9% to 7.7%

By group

CABGvs PCI
difference 1.3% (95% CI −4.9% to 7.7%)

Further findings

OutcomeCABGPCIDifference (95% CI)
Adjusted primary event rate, intermediate SYNTAX (23-32) group (n = 346; 163 CABG, 183 PCI) · 4 yearsAdjusted10.6%18.3%−7.6% (−16.1% to 0.9%)
OutcomeCABGPCIP value
SYNTAX score, descriptive cohort27.3 ± 11.015.3 ± 8.6P < 0.0001

Revascularization method by SYNTAX score

Low SYNTAX scores: underwent PCI
87.1%
High SYNTAX scores: underwent CABG
72.6%

Original publication

Use of coronary artery bypass graft surgery and percutaneous coronary intervention and associated outcomes in the ISCHEMIA trial. Am Heart J. Published 20 May 2025. doi:10.1016/j.ahj.2025.05.009

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.